Latest Patient Square Capital LP Stock Portfolio
$563Million– No. of Holdings #29
Patient Square Capital LP Performance:
2026 Q1: 11.12%YTD: 11.12%2025: 58.45%
Performance for 2026 Q1 is 11.12%, and YTD is 11.12%, and 2025 is 58.45%.
About Patient Square Capital LP and 13F Hedge Fund Stock Holdings
On 2026-05-15, the fund reported it's updated stock portfolio. In the 13F Holdings report, Patient Square Capital LP reported an equity portfolio of $563.6 Millions as of 31 Mar, 2026.
The top stock holdings of Patient Square Capital LP are ROIV, ARGX, INSM. The fund has invested 40.1% of it's portfolio in ROIVANT SCIENCES LTD and 4.8% of portfolio in ARGENX SE.
The fund managers got completely rid off TERNS PHARMACEUTICALS INC (TERN), LIQUIDIA CORPORATION (LQDA) and OCULAR THERAPEUTIX INC (OCUL) stocks. They significantly reduced their stock positions in SPYRE THERAPEUTICS INC (AGLE), INSMED INC (INSM) and DIANTHUS THERAPEUTICS INC. Patient Square Capital LP opened new stock positions in BELITE BIO INC (BLTE), LEGEND BIOTECH CORP (LEGN) and NEKTAR THERAPEUTICS (NKTR). The fund showed a lot of confidence in some stocks as they added substantially to HARROW INC (HROW), DBV TECHNOLOGIES S A (DBVT) and ARCUTIS BIOTHERAPEUTICS INC (ARQT).
The top stock holdings of Patient Square Capital LP are ROIV, ARGX, INSM. The fund has invested 40.1% of it's portfolio in ROIVANT SCIENCES LTD and 4.8% of portfolio in ARGENX SE.
The fund managers got completely rid off TERNS PHARMACEUTICALS INC (TERN), LIQUIDIA CORPORATION (LQDA) and OCULAR THERAPEUTIX INC (OCUL) stocks. They significantly reduced their stock positions in SPYRE THERAPEUTICS INC (AGLE), INSMED INC (INSM) and DIANTHUS THERAPEUTICS INC. Patient Square Capital LP opened new stock positions in BELITE BIO INC (BLTE), LEGEND BIOTECH CORP (LEGN) and NEKTAR THERAPEUTICS (NKTR). The fund showed a lot of confidence in some stocks as they added substantially to HARROW INC (HROW), DBV TECHNOLOGIES S A (DBVT) and ARCUTIS BIOTHERAPEUTICS INC (ARQT).
Patient Square Capital LP Equity Portfolio Value
Last Reported on: 15 May, 2026
Patient Square Capital LP Annual Return Estimates Vs S&P 500
Our best estimate is that Patient Square Capital LP made a return of 11.12% in the last quarter. In trailing 12 months, it's portfolio return was 98.36%.
- Performance
- S&P 500
New Buys
| Ticker | $ Bought |
|---|---|
| belite bio inc | 18,604,100 |
| legend biotech corp | 17,909,100 |
| nektar therapeutics | 15,109,500 |
| merck & co inc | 9,623,200 |
| definium therapeutics inc | 6,255,900 |
| protara therapeutics inc | 5,370,710 |
| cytomx therapeutics inc. | 5,103,210 |
New stocks bought by Patient Square Capital LP
Additions
| Ticker | % Inc. |
|---|---|
| harrow inc | 2,249 |
| dbv technologies s a | 93.16 |
| arcutis biotherapeutics inc | 90.78 |
| cogent biosciences inc | 87.79 |
| xenon pharmaceuticals inc | 66.3 |
| perspective therapeutics inc | 43.45 |
| argenx se | 41.22 |
| beone medicines ltd | 16.2 |
Additions to existing portfolio by Patient Square Capital LP
Reductions
| Ticker | % Reduced |
|---|---|
| spyre therapeutics inc | -99.33 |
| insmed inc | -41.01 |
| dianthus therapeutics inc | -37.41 |
| enliven therapeutics inc | -35.09 |
| allogene therapeutics inc | -30.5 |
| kymera therapeutics inc | -28.06 |
| mirum pharmaceuticals inc | -23.00 |
| celcuity inc | -20.83 |
Patient Square Capital LP reduced stake in above stock
Sold off
| Ticker | $ Sold |
|---|---|
| ocular therapeutix inc | -5,948,600 |
| amylyx pharmaceuticals inc | -4,228,000 |
| terns pharmaceuticals inc | -12,928,000 |
| avalo therapeutics inc | -5,665,300 |
| liquidia corporation | -7,829,230 |
| disc medicine inc | -5,876,340 |
Patient Square Capital LP got rid off the above stocks
Sector Distribution
Patient Square Capital LP has about 78.8% of it's holdings in Healthcare sector.
- Healthcare
- Others
| Sector | % |
|---|---|
| Healthcare | 78.8 |
| Others | 21.2 |
Market Cap. Distribution
Patient Square Capital LP has about 50.7% of it's portfolio invested in the large-cap and mega-cap stocks.
- LARGE-CAP
- UNALLOCATED
- MID-CAP
- SMALL-CAP
- MEGA-CAP
| Category | % |
|---|---|
| LARGE-CAP | 44.7 |
| UNALLOCATED | 21.2 |
| MID-CAP | 18.6 |
| SMALL-CAP | 8.6 |
| MEGA-CAP | 6 |
Stocks belong to which Index?
About 24.3% of the stocks held by Patient Square Capital LP either belong to S&P 500 or RUSSELL 2000 index.
- Others
- RUSSELL 2000
- S&P 500
| Index | % |
|---|---|
| Others | 75.7 |
| RUSSELL 2000 | 22.6 |
| S&P 500 | 1.7 |
Patient Square Capital LP Holdings Map
This heatmap illustrates the top 50 positions within the fund's portfolio.
Current Stock Holdings of Patient Square Capital LP
Patient Square Capital LP has 29 stocks in it's portfolio. About 73.3% of the portfolio is in top 10 stocks. EYPT proved to be the most loss making stock for the portfolio. ROIV was the most profitable stock for Patient Square Capital LP last quarter.
Last Reported on: 15 May, 2026| Ticker | Namesorted ascending | % Portfolio | Shares Held | $ Value | Type | % Change | Options | |
|---|---|---|---|---|---|---|---|---|
| AGLE | spyre therapeutics inc | 0.01 | 1,000 | 50,440 | reduced | -99.33 | ||
| ALLO | allogene therapeutics inc | 1.49 | 3,450,000 | 8,418,000 | reduced | -30.5 | ||
| AMLX | amylyx pharmaceuticals inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| ARGX | argenx se | 4.76 | 36,718 | 26,813,300 | added | 41.22 | ||
| ARQT | arcutis biotherapeutics inc | 1.68 | 400,645 | 9,439,200 | added | 90.78 | ||
| ASMB | assembly biosciences inc | 0.67 | 136,315 | 3,782,740 | added | 7.33 | ||
| AVTX | avalo therapeutics inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| BGNE | beone medicines ltd | 4.24 | 80,542 | 23,918,600 | added | 16.2 | ||
| BLTE | belite bio inc | 3.30 | 116,684 | 18,604,100 | new | |||
| CELC | celcuity inc | 1.92 | 95,000 | 10,843,300 | reduced | -20.83 | ||
| COGT | cogent biosciences inc | 4.07 | 596,000 | 22,940,000 | added | 87.79 | ||
| CTMX | cytomx therapeutics inc. | 0.90 | 1,085,790 | 5,103,210 | new | |||
| DBVT | dbv technologies s a | 2.57 | 693,534 | 14,487,900 | added | 93.16 | ||
| EYPT | eyepoint inc | 1.82 | 795,000 | 10,247,600 | added | 1.92 | ||
| HROW | harrow inc | 1.03 | 165,209 | 5,825,270 | added | 2,249 | ||
| INSM | insmed inc | 4.57 | 157,500 | 25,754,400 | reduced | -41.01 | ||
| KYMR | kymera therapeutics inc | 1.48 | 100,000 | 8,329,000 | reduced | -28.06 | ||
| LEGN | legend biotech corp | 3.18 | 990,000 | 17,909,100 | new | |||
| LQDA | liquidia corporation | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| MIRM | mirum pharmaceuticals inc | 3.77 | 230,000 | 21,247,400 | reduced | -23.00 | ||